AprilBio Amends Joint Investment Agreement Party in Management Change with TKG Huchems; No Change to Core Financial Terms

AprilBio has filed an amendment to the management change agreement, confirming that the joint investment agreement party has been changed from IMM Asset Management to IMM Healthcare No. 8.
This is an administrative correction due to a transfer of status among existing parties. There is no change to the core financial terms: 150 billion won capital raise, 14.9% dilution, and issue price of 42,953 won per share.
The board composition of three TKG-nominees and two major shareholder-nominees, as well as existing option rights, remain unchanged.
[AI Summary]This amendment is a procedural correction reflecting a change in the joint investment agreement party, with no material impact on shareholder value. Investors should maintain their assessment based on the previously disclosed 14.9% dilution and TKG's financial strength.